Abstract
Abraxane (nab-paclitaxel) is a member of the group of nano chemotherapeutics. It is approved for metastatic breast cancer and non small cell lung cancer. Trials for several cancer types including gynecological cancers, head and neck, and prostatic cancer are being studied. In this study, the antiproliferative and apoptotic effect of abraxane was evaluated on HeLa cell line originated from human cervix carcinoma. Three different doses (D1=10 nM, D2=50 nM, D3=100 nM) were administered to HeLa cells for 24, 48 and 72 h. The 50 nM dose of abraxane decreased DNA synthesis from 4.62-0.08%, mitosis from 3.36-1.89% and increased apoptosis from 10.6-30% at 72 h. Additionally, tripolar metaphase plates were seen in mitosis preparations. In this study, abraxane effected cell kinetic parameters significantly. This results are consistent with other studies in the literature.
Highlights
Paclitaxel (PTX) is a chemotherapeutic agent that has been used to treat a variety of cancers, including primary epithelial ovarian, colon, non-small cell lung and metastatic breast cancers
Determination of optimal dose with mitotic index analysis In this study three different doses of Abraxane (D1=10nM, dose 2 (D2)=50nM, dose 3 (D3)=100nM) were applied to HeLa cell culture for 24, 48 and 72 h and anti mitotic effects of these doses were evaluated with mitotic index analysis
It was seen that there were a significant difference between experimental groups (p
Summary
Paclitaxel (PTX) is a chemotherapeutic agent that has been used to treat a variety of cancers, including primary epithelial ovarian, colon, non-small cell lung and metastatic breast cancers. Its mechanism of action is through stabilization of microtubules which promotes polymerization of tubulin, causing cell death by disrupting the dynamics necessary for cell division (Lin et al, 2012) It disrupts the dynamic equilibrium within the microtubule system and blocks cells in the late G2 phase and M phase of the cell cycle, thereby inhibiting cell replication (Danhier et al, 2009). A number of alternative formulations were investigated for the solubilization of PTX, including liposomes, microspheres, nanoparticles and polymeric micelles. The rationale behind this approach is to increase antitumor efficacy while reducing systemic side effects. Nanoparticles can escape from the vasculature through the leaky endothelial tissue that surrounds the tumor and accumulate in certain solid tumors by the so-called Enhanced Permeation and Retention (EPR) effect (Danhier et al, 2009)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
